BIOFLUIDICA, INC.

From the company

BioFluidica is a privately held biotechnology and liquid biopsy company that developed the LiquidScan platform, which isolates and analyzes liquid biopsy biomarkers including rare cells, extracellular vesicles (exosomes), and cfDNA on one fully automated platform. LiquidScan combines microfluidics, immunoaffinity chemistries, automation hardware, and workflow optimization. The platform has been clinically tested on nine cancer and prenatal patient samples and is used for research applications. BioFluidica also develops scientific instruments, reagents, a